Although anti-TNFα drugs are approved for many other chronic immune-mediated inflammatory diseases, they are still used off-label for non-infectious posterior uveitis, with the exception of adalimumab which has been approved for this indication [76,80,81]. This evidence concerns the gene TNF and posterior uveitis.